The PTPRA antibody targets protein tyrosine phosphatase receptor type A (PTPRA), a member of the protein tyrosine phosphatase (PTP) family. PTPRA plays a critical role in regulating cellular signaling by dephosphorylating tyrosine residues on target proteins, thereby modulating processes like cell growth, differentiation, and oncogenic transformation. Structurally, PTPRA contains an extracellular region with fibronectin-type III-like domains, a single transmembrane segment, and an intracellular catalytic domain. Its activity counterbalances tyrosine kinase signaling, maintaining equilibrium in pathways such as MAPK, Src, and growth factor receptor cascades.
PTPRA is implicated in various diseases, including cancer, where it may act as a tumor suppressor or promoter depending on context. For example, it can inhibit Src-family kinase activity in some cancers while promoting EGFR signaling in others. Additionally, PTPRA is linked to insulin resistance and neurodegenerative disorders. Antibodies against PTPRA are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect endogenous PTPRA in cell lines, tissues, or disease models. Validated antibodies help clarify PTPRA's dual roles in signaling and pathology, aiding therapeutic target exploration.